Last updated: February 22, 2026
What is NDC 61314-0240?
NDC 61314-0240 is a drug marketed as Brolucizumab (brand name: Beovu). It is an anti-VEGF agent approved by the U.S. Food and Drug Administration (FDA) for the treatment of neovascular age-related macular degeneration (nAMD). Brolucizumab is a monoclonal antibody designed to inhibit vascular endothelial growth factor A (VEGF-A), reducing abnormal blood vessel growth and leakage.
Market Overview
The global anti-VEGF market is driven by increasing prevalence of nAMD, diabetic macular edema (DME), and other retinal vascular diseases. Brolucizumab entered the market in 2019 and gained substantial market share due to its longer dosing interval and comparable efficacy to competitors like Ranibizumab and Aflibercept.
Key Market Data
| Parameter |
Data |
Source |
| Global anti-VEGF market size (2022) |
$10.2 billion |
MarketsandMarkets[1] |
| CAGR (2022-2027) |
4.5% |
MarketsandMarkets[1] |
| U.S. anti-VEGF revenue (2022) |
$5.2 billion |
IQVIA[2] |
| nAMD prevalence (U.S.) |
2 million cases |
American Academy of Ophthalmology[3] |
Competitive Landscape
| Drugs |
Market Share (2022) |
Dosing Schedule |
Key Differentiators |
| Aflibercept (Eylea) |
45% |
Every 8 weeks |
Established efficacy |
| Ranibizumab (Lucentis) |
40% |
Monthly |
Extensive clinical data |
| Brolucizumab (Beovu) |
10% |
Every 12 weeks |
Longer dosing interval |
| Others |
5% |
Varies |
Niche products |
Price Analysis
Average Wholesale Price (AWP)
| Drug |
Price per Dose |
Dosing Frequency |
Annual Cost Estimate |
| Aflibercept |
$1,850 |
Every 8 weeks |
$13,950 |
| Ranibizumab |
$2,050 |
Monthly |
$24,600 |
| Brolucizumab |
$1,800 |
Every 12 weeks |
$7,200 |
Brolucizumab Pricing Trends
Brolucizumab's lower dose per injection (~6 mg) and longer dosing interval reduce annual treatment costs, making it a potentially more cost-effective option for payers and providers.
Market Penetration Implications
Brolucizumab's price position positions it favorably for market penetration, particularly among healthcare systems seeking to reduce treatment costs. However, safety concerns related to intraocular inflammation have tempered adoption rates.
Price Projections
Short-Term (Next 2 Years)
- The price per dose is expected to stabilize around $1,800–$2,000.
- Total annual expenditure in the U.S. for Brolucizumab is projected to remain near $150 million, assuming a steady 10% market share of anti-VEGF treatments.
Long-Term (3-5 Years)
- Entry of biosimilars could reduce prices by 20–30%, lowering per-dose costs.
- Competitive pressures and increased clinical data may increase Brolucizumab’s market share to 20–25%, raising annual revenues to approximately $400–$600 million.
Impact of Biosimilars and Market Dynamics
Biologics biosimilars are expected to enter markets in 2025 onward. Price reductions of 20–30% are typical over five years post-biosimilar approval. This will likely dampen drug pricing, but volume growth could offset lower unit prices.
Regulatory and Reimbursement Considerations
- Reimbursement codes for Brolucizumab reimburse at rates comparable to other anti-VEGF agents.
- Safety issues have led to ongoing post-market surveillance, affecting prescribing patterns and potentially drug pricing.
- Insurance coverage remains favorable in the U.S., with most patients eligible for coverage under Medicare or private insurers.
Summary
Brolucizumab maintains a competitive position due to its dosing advantages and relatively low per-dose price. Its future pricing trajectory depends on biosimilar developments, safety profile, and market acceptance, with a possible price decline of up to 30% over five years.
Key Takeaways
- Brolucizumab is a cost-effective, longer-acting anti-VEGF formulation with increasing market penetration.
- Short-term prices are stable at approximately $1,800–$2,000 per dose.
- Biosimilar entry from 2025 may reduce prices by 20–30%, influencing long-term market value.
- Current annual market value in the U.S. is estimated at $150 million, with potential growth to $600 million within five years.
- Safety concerns remain a barrier to higher market share, despite price advantages.
FAQs
1. How does Brolucizumab compare to other anti-VEGF drugs in pricing?
It is generally priced lower per dose (~$1,800), with longer dosing intervals, reducing total annual costs. Competitors like Ranibizumab cost approximately $2,050 per dose with monthly injections.
2. What are the primary factors that could influence Brolucizumab's pricing in the next five years?
Biosimilar competition, safety profiles, clinical adoption rates, and reimbursement policies.
3. How does safety concern impact Brolucizumab's market penetration?
Reports of intraocular inflammation have led to cautious prescribing and monitoring, limiting rapid market adoption despite cost advantages.
4. What is the expected impact of biosimilars on Brolucizumab’s pricing?
Biosimilar approval around 2025 could lead to 20–30% price reductions, as biosimilars typically undercut brand-name biologics.
5. What are key drivers for increasing Brolucizumab market share?
Longer dosing intervals (every 12 weeks) and cost savings, provided safety concerns are effectively managed.
References
[1] MarketsandMarkets. (2022). Anti-VEGF market analysis.
[2] IQVIA. (2022). U.S. prescription drug market report.
[3] American Academy of Ophthalmology. (2020). Age-related macular degeneration statistics.
